biome

(redirected from BIOM)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia.
Related to BIOM: BOM

bi·ome

 (bī′ōm′)
n.
A major regional or global biotic community, such as grassland or desert, characterized chiefly by its prevailing climate and vegetation.

biome

(ˈbaɪˌəʊm)
n
(Environmental Science) a major ecological community, extending over a large area and usually characterized by a dominant vegetation. See formation6
[C20: from bio- + -ome]

bi•ome

(ˈbaɪ oʊm)

n.
a major geographic region that contains a distinctive community of plants, animals, fungi, etc.
[1915–20]
click for a larger image
biome

bi·ome

(bī′ōm′)
A large community of plants and animals that occupies a distinct region defined by its climate and dominant vegetation. Grassland, tundra, desert, tropical rain forest, and deciduous and coniferous forests are all examples of biomes.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.biome - a major biotic community characterized by the dominant forms of plant life and the prevailing climatebiome - a major biotic community characterized by the dominant forms of plant life and the prevailing climate
biotic community, community - (ecology) a group of interdependent organisms inhabiting the same region and interacting with each other
desert - arid land with little or no vegetation
grassland - land where grass or grasslike vegetation grows and is the dominant form of plant life
timberland, woodland, forest, timber - land that is covered with trees and shrubs
Translations

biome

[ˈbaɪəʊm] Nbiomedio m
References in periodicals archive ?
We are encouraged that dirucotide has demonstrated an effect on certain clinical measures of disease progression, this time in the earlier form of the disease," said Kevin Giese, president and CEO of BioMS Medical.
We are pleased that our partner has recognized the outcome of the interim analysis as a significant positive event," said Kevin Giese, president and CEO of BioMS Medical.
worldwide rights to BioMS Medical's lead multiple sclerosis (MS) compound,
BioMS Medical licenses these patents on an exclusive worldwide basis from the University of Alberta.
People with secondary progressive multiple sclerosis are currently being enrolled in a phase II/III trial outside of the United States that will evaluate the impact of an intravenously administered synthetic peptide that targets a portion of myelin basic protein related to disease progression, according to the manufacturer, BioMS Medical Corp.
Kevin Giese, President, CEO and Director of BioMS Medical and Mr.
Based on the DSMB decision, Eli Lilly and Company has agreed to provide the US$10 million milestone payment to BioMS as part of the terms of the licensing and collaboration agreement.
BioMS Medical Corp (TSX: MS), Edmonton, Canada, a leading developer of products for the treatment of multiple sclerosis (MS), has received clearance from the United States Food and Drug Administration (FDA) of its Investigational New Drug Application (IND) for the initiation of a pivotal phase III clinical trial to investigate the use of MBP8298 as a treatment for patients with secondary progressive MS.
EDMONTON, Alberta, January 22 /PRNewswire/ -- BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), announced today that it has received clearance from the United States Food and Drug Administration (FDA) of its Investigational New Drug Application (IND) for the initiation of a pivotal phase III clinical trial to investigate the use of MBP8298 as a treatment for patients with secondary progressive MS.
BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has completed patient recruitment in its pivotal phase II/III clinical trial of MBP8298 for the treatment of secondary progressive MS.